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ABSTRACT
Objectives: To assess the cost-effectiveness of
optometrist-led follow-up monitoring reviews for
patients with quiescent neovascular age-related
macular degeneration (nAMD) in community settings
(including high street opticians) compared with
ophthalmologist-led reviews in hospitals.
Design: A model-based cost-effectiveness analysis
with a 4-week time horizon, based on a ‘virtual’ non-
inferiority randomised trial designed to emulate a
parallel group design.
Setting: A virtual internet-based clinical assessment,
conducted at community optometry practices, and
hospital ophthalmology clinics.
Participants: Ophthalmologists with experience in the
age-related macular degeneration service; fully qualified
optometrists not participating in nAMD shared care
schemes.
Interventions: The participating optometrists and
ophthalmologists classified lesions from vignettes and
were asked to judge whether any retreatment was
required. Vignettes comprised clinical information,
colour fundus photographs and optical coherence
tomography images. Participants’ classifications were
validated against experts’ classifications (reference
standard). Resource use and cost information were
attributed to these retreatment decisions.
Main outcome measures: Correct classification of
whether further treatment is needed, compared with a
reference standard.
Results: The mean cost per assessment, including the
subsequent care pathway, was £411 for optometrists
and £397 for ophthalmologists: a cost difference of
£13 (95% CI −£18 to £45). Optometrists were non-
inferior to ophthalmologists with respect to the overall
percentage of lesions correctly assessed (difference
−1.0%; 95% CI −4.5% to 2.5%).
Conclusions: In the base case analysis, the slightly
larger number of incorrect retreatment decisions by
optometrists led to marginally and non-significantly
higher costs. Sensitivity analyses that reflected different
practices across eye hospitals indicate that shared care
pathways between optometrists and ophthalmologists
can be identified which may reduce demands on scant
hospital resources, although in light of the uncertainty
around differences in outcome and cost it remains
unclear whether the differences between the 2 care
pathways are significant in economic terms.
Trial registration number: ISRCTN07479761;
Pre-results.
Strengths and limitations of this study
▪ This is the first study to evaluate the cost-
effectiveness of optometrist-led follow-up moni-
toring reviews for patients with quiescent treated
neovascular age-related macular degeneration
(nAMD) in community settings versus
ophthalmologist-led monitoring reviews within
the hospital eye service.
▪ Our results indicate that a cost-effective model of
shared care between community optometrists
and ophthalmologists in the management of
nAMD may be achievable.
▪ Devolving responsibilities for monitoring patients
to community optometrists may be a viable
option to reduce the burden imposed on the
hospital eye service by the new nAMD drugs.
▪ Given the ‘virtual’ nature of the trial, identification
of the resource items and associated costs of
providing follow-up monitoring reviews in com-
munity optometry practices was a particularly
challenging task for optometrists. They had to
refer to a hypothetical shared care scheme (ie,
not currently routine), which may have affected
the accuracy of some responses.
▪ The analysis used a 4-week time horizon, used
mean imputation for missing data and made
assumptions about the treatment pathway that
would be followed if a shared care scheme was
introduced in practice.
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INTRODUCTION
Neovascular age-related macular degeneration (nAMD)
is a common disorder of the ageing eye, which if left
untreated leads to severe central visual impairment. The
current standard of care is treatment with biological
drugs, which bind to or inhibit vascular endothelial
growth factor (VEGF); these include ranibizumab
(Lucentis) and bevacizumab (Avastin). These anti-VEGF
therapies require intravitreal injections at 4–8-week inter-
vals. Following multiple treatments, nAMD lesions
become quiescent,1 2 but there is a high risk of reactiva-
tion and regular review by experienced retinal specialists
in hospital is routine clinical practice in many coun-
tries.3–5 This model of care results in ∼8–10 visits per
year to a hospital eye service (HES) for most patients,
which is expensive for healthcare systems and places a
substantial burden on patients and their carers in terms
of travel time and costs, and disruption to daily activ-
ities.3–5
Studies based in the UK estimate that total direct
National Health Service (NHS) expenditure in eye
health services totalled £2.15 billion in 2008,6 a ﬁgure
which increased by 22.8% in 2013.7 Despite such an
increase, the UK has the lowest ratio of consultant
ophthalmologists per capita in the European Union,8
and this limited clinical capacity may undermine
optimal care and timely access to potentially sight-saving
treatments. For nAMD, much of the patient care discus-
sion has centred on the expenditure allocated to the
choice of anti-VEGF therapies,2 rather than the develop-
ment of shared care options to address the increase in
nAMD referrals to HES.
In glaucoma9–11 and diabetic retinopathy,12 13 innova-
tive shared care delivery models have been proposed
and/or implemented, whereby non-medical eye care
professionals, such as community optometrists (eg, high
street opticians), provide some of the care, thereby alle-
viating the burden on the HES.14 15 Devolving the moni-
toring of patients with quiescent nAMD disease to
community optometrists may also be a clinically and eco-
nomically viable solution to reduce burden on the HES,
the patients and their carers. To the best of our knowl-
edge, however, there is no evidence at present assessing
such model of shared care. The ECHoES (Effectiveness
of Community vs Hospital Eye Service) trial was, there-
fore, designed and undertaken to evaluate whether a
shared care model between community optometrists
and ophthalmologists for treatment of nAMD could be
clinically effective and cost-effective. This paper reports
the results of the cost-effectiveness analysis.
METHODS
The ECHoES trial was a ‘virtual’ non-inferiority rando-
mised trial conceived to emulate a parallel group design.
Optometrists and ophthalmologists made decisions
about the reactivation status of lesions by reviewing vign-
ettes, consisting of two sets of retinal images (baseline
and index), including colour fundus and optical coher-
ence tomogram (OCT) images, with accompanying clin-
ical and demographic information, rather than by
examining actual patients. In baseline images the lesion
was quiescent; in index images the lesion could have
been quiescent, suspicious or reactivated. Ninety-six par-
ticipants (48 optometrists and 48 ophthalmologists)
each assessed 42 vignettes in a randomised balanced
incomplete block design; each of the 288 vignettes was
assessed by 7 optometrists and 7 ophthalmologists
(n=2016 total observations). Participants judged whether
the lesion had reactivated or not in the index set of
images. Full details of the trial methods are published
elsewhere.16 17
Economic evaluation
A model-based cost-effectiveness analysis was conducted
to compare the cost-effectiveness of optometrist-led
follow-up monitoring reviews for patients with quiescent
nAMD in community settings versus HES
ophthalmologist-led monitoring appointments. The
evaluation was undertaken using established guidelines
for conducting and reporting cost-effectiveness ana-
lyses.18 19 The perspective for the analysis was that of the
UK NHS, following National Institute for Health and
Care Excellence (NICE) recommendations.18 Owing to
the virtual nature of the trial, it was not possible to
collect data on patients’/carers’ time off work/usual
activities and travel costs to undergo eye assessment to
inform a wider societal perspective. The economic evalu-
ation assessed the cost per ‘correct’ retreatment deci-
sion, with ‘correct’ indicating that the reference
standard lesion classiﬁcation (as based on the judge-
ments of three medical retina experts16) and the trial
participants’ judgements on the status of the lesion coin-
cided. Since monitoring visits are typically conducted at
4-week intervals, the time horizon for our analysis was
4 weeks after the consultation in which patients were
assessed by either an ophthalmologist or an optometrist
to allow inclusion of downstream costs from retreatment
decisions (eg, the costs of administering an anti-VEGF
injection). Any costs and health consequences arising
from incorrect treatment decisions beyond this 4-week
time horizon were assumed to be captured within our
measure of effectiveness (the number of correct retreat-
ment decisions). No data are available on the effect of
delaying anti-VEGF treatment after reactivation and
modelling the costs and health consequences from
incorrect retreatment decisions would therefore have
relied entirely on assumptions or expert opinion. Owing
to the short time horizon for analysis, discounting was
not applied to costs or effects. We assumed that the costs
and retreatment decisions would be constant over time
and not vary with the number of previous monitoring
consultations, as we are unaware of any reason why the
incremental cost of monitoring or the probability of
optometrists and ophthalmologists making correct
retreatment decisions would be any different for the
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second or subsequent monitoring consultations than it
would for the ﬁrst consultation.
Measurement and valuation of resource use
Measurement and valuation of resources used to
perform a monitoring review in community optometric
practices, required designing a bespoke questionnaire
(available in online supplementary material—Resource
use and cost questionnaire), which was completed by
optometrists in the ECHoES trial. The questionnaire was
developed by the ECHoES trial team (health econo-
mists, clinicians and optometrists) with external input
from community optometrists not participating in
the trial.
The resource use questionnaire asked respondents to
describe the types and quantities of resources used for
an ‘average’ monitoring review, which included staff
time and equipment items, and report their unit costs
(staff salaries and cost of equipment). As the trial was
virtual, the optometrists also had to anticipate what
resource items they did not currently have in the prac-
tice but which they would need to provide the monitor-
ing service. In order to capture the cost of setting up
facilities and purchasing/maintaining equipment
required for the new service, participants were asked to
provide details of any refurbishment work that would be
required and for details of all necessary equipment,
including its cost and annual service cost. The cost of
equipment was annuitised using a 3.5% discount rate20
based on assumptions about the likely life span of equip-
ment, then divided by the estimated number of poten-
tial patients that participating optometrists estimated
would use the service annually. Costs associated with
training trial participants included the 2-hour
webinar16 17 provided as part of the trial, time spent by
participants reviewing the webinar and consulting other
resources (as reported in the participants’ question-
naire), and time spent by the ECHoES trial clinicians in
preparing and delivering the webinar training (clini-
cians’ self-report). Details are reported in online
supplementary tables A.1 and A.2 in the online
supplementary material. Value-added tax was excluded
from costs as recommended.18 20
The costs associated with ophthalmologists performing
the monitoring assessments and the cost of administer-
ing intravitreal injections were based on data from the
UK Inhibition of VEGF in Age-related choroidal
Neovascularisation (IVAN) trial, in which a very detailed
microcosting study was undertaken.21 22 The consult-
ation costs taken from IVAN were adjusted for inﬂation
using the Hospital and Community Health Services Pay
and Prices Index 2010/2011 and 2012/2013.23
Estimation of total costs and cost-effectiveness across the
treatment pathway
In order to generate an estimate of the total cost per
correct retreatment decision, it was ﬁrst necessary to
develop an ‘acceptable’ model of shared-care between
community optometrists and hospital ophthalmologists
for co-management of follow-up appointments for
patients with nAMD. The model was developed with the
input of clinicians and optometrists in the ECHoES trial
team, drawing from direct experiences of current clin-
ical practice and participation in other similar models of
shared care in eye health.
The care pathway followed by ophthalmologists in the
HES reﬂected clinical practice in hospital settings at the
time the trial was conducted (ﬁgure 1). The care
pathway followed by community optometrists (ﬁgure 2)
assumed that patients who were referred back to the
HES with what community optometrists judged to be
‘reactivated lesions’, would attend a further HES moni-
toring review before the intravitreal injection. The
rationale behind this choice was that, especially in the
initial phases of implementation of the new shared care
model, a second clinical opinion could help identify
patients mistakenly classiﬁed as having reactivated
lesions by cautious optometrists, avoiding unnecessary
expensive treatments. For simplicity, we assumed that
this additional consultation would identify all quiescent
or suspicious lesions that had been incorrectly referred
by optometrists. We acknowledge that we made certain
assumptions and this is a limitation of our present study,
however, modelling the sensitivity and speciﬁcity of this
HES review would have complicated the analysis and
required additional assumptions, which, in the absence
of any empirical evidence, could be only speculative.
Having established the new hypothetical model of
shared care, we developed the two decision trees
(ﬁgures 1 and 2). These show pathways that would pos-
sibly be generated from the treatment assessments in the
study, based on participants’ classiﬁcation of each
vignette and the reference standard lesion classiﬁcation.
The reference standard lesion classiﬁcation was the
benchmark to establish whether the optometrists’ and
ophthalmologists’ in the trial correctly judged the lesion
status of each vignette. The model allowed for the short-
term cost consequences of incorrect retreatment deci-
sions by both optometrists and HES ophthalmologists.
The lesion judgements made by the groups of ophthal-
mologists and optometrists in the study were then used
to populate the model, and the associated costs for dif-
ferent pathways were calculated. In this way an average
cost for each alternative care pathway was generated. An
‘incorrect’ decision implied that patients would have
missed an opportunity for prompt treatment, had an
unnecessary repeat monitoring appointment, or would
have received unnecessary anti-VEGF injections.
Online supplementary tables A.1 and A.2 in the
online supplementary material summarise the unit costs
that were attached to the resource use information. The
base case analysis assumed that ranibizumab (Lucentis)
would be the drug of choice; its cost was £742 per
dose.24 The ECHoES costing questionnaire was sent to
61 optometrists (who completed webinar training). So
as to not overburden participants, the costing
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questionnaire was not a compulsory section, which
reduced the number of returned questionnaires to 40
out of the 61 questionnaires (66%). Fifty-ﬁve of the 61
invited optometrists (90%) replied to a separate feed-
back questionnaire, which, in addition to some questions
about how the training provided was received by partici-
pants, also contained information on the time spent on
training by optometrists. To estimate the cost per moni-
toring review for each community optometry practice,
information from the costing and the feedback question-
naires were merged using the participant’s unique and
anonymised identiﬁer. Seven per cent of data from the
completed questionnaires were missing (see online
supplementary table A.3 in the online supplementary
material). For consistency with the procedure adopted
for costing consultations in the IVAN trial, mean values
of the relevant variables were imputed whenever the
information was missing. The total cost of a monitoring
review performed in a community optometry practice,
stratiﬁed by cost categories, is reported in online
supplementary table A.4 in the online supplementary
material. For the costs of the ophthalmologists’ monitor-
ing reviews in hospital, data from the IVAN trial were
used, which provided 28 estimates of the cost of
clinician-led HES monitoring reviews from different
clinics at various hospitals. All costs are reported in
2013/2014 prices in British pounds (£).
In order to allow for the variability between clinics
and imprecision around the mean cost per clinic, we fol-
lowed an approach similar to that used in the IVAN
trial21 to randomly assign consultation costs to each
observation. Details of the random allocation procedure
for costs are reported in the online supplementary
material (‘Cost model—random allocation’ section).
This approach propagates uncertainty around the
costing into the economic evaluation, and ensures that
the analysis is based on the average cost per
consultation.
Given the large sample size and in the interest of sim-
plicity, we used parametric methods based on the
assumption of Gaussian distributions to estimate CIs and
cost-effectiveness acceptability curves (CEACs).25 After
calculating the costs for each vignette for each partici-
pant, we estimated regression models predicting costs
and the probability of a correct retreatment decision as
a function of whether the participant was an optometrist
rather than an ophthalmologist, adjusting SEs for clus-
tering by participant and correlations between costs and
Figure 1 Decision tree for hospital ophthalmologist review.
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decision accuracy. The resulting SEs were used to calcu-
late CIs, conﬁdence ellipses and CEACs, which indicate
the probability that the optometrist-led monitoring
reviews are cost-effective compared with the
ophthalmologist-led reviews for a range of potential
threshold values that the NHS would be willing to pay
for an additional unit of effect.26 Five sensitivity analyses
tested different assumptions about the type of treatment
received when a lesion was assessed as reactivated, and
different shared care pathways between optometrists and
ophthalmologists—given that the shared model of care
is still hypothetical and may vary between hospitals (see
the sensitivity analysis sections in the online
supplementary material, supplementary tables A.5–A.14
and supplementary ﬁgures A.2–A.11 for further details):
1. Reactivated lesions were assumed to receive a course
of three injections of ranibizumab at three injection
consultations (vs one injection in the base case);
2. Reactivated lesions were assumed to receive one aﬂi-
bercept injection during one injection consultation;
3. Reactivated lesions were assumed to receive one beva-
cizumab injection during one injection consultation;
4. Only the cost of a monitoring review was considered
rather than the cost of the whole care pathway;
5. Assuming that an ophthalmologist would re-examine
the OCT images taken by optometrists whenever the
optometrist judgement was ‘lesion reactivated’
(rather a complete monitoring review at the HES as
in the base case).
All analyses were undertaken using STATA V.12.1
(StataCorp, College Station, Texas, USA).
A post hoc χ2 test conducted in STATA was used to
determine if there was a statistically signiﬁcant difference
in the proportion of truly quiescent vignettes that were
classed as reactivated between ophthalmologists and
optometrists.16 17
RESULTS
Resource use and costs
Online supplementary table A.4 in the online
supplementary material reports the total cost of a moni-
toring review performed in a community optometry
practice, stratiﬁed by cost categories. In terms of
Figure 2 Decision tree for community optometrist review.
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equipment resources required to perform a monitoring
review, 97.5% of community practices participating in
the trial owned a colour fundus camera, but <50% had a
projector or a retroilluminated light box for displaying
an Early Treatment of Diabetic Retinopathy Study
(ETDRS) visual acuity chart. OCT equipment was owned
by 45% (18/40) of the optometrists who completed the
questionnaires. The average ﬂoor space of a community
practice was reported as being 173 m2 (interquantile
range=97) comprising, on average, 3.5 rooms (SD=2.20).
Just over half of the respondents reported that their
premises would require modiﬁcations to assess patients
with nAMD, but that these would mainly consist of modi-
fying existing rooms, rather than radical structural
changes involving building work.
In terms of stafﬁng, optometrists stated that they
would undertake most of the required tasks within a
monitoring review, that is, take patient history, carry out
the clinical examination, visual assessment (including
administration of 1% tropicamide drops) and the ﬁnal
assessment. However, one-third of respondents stated
that they would share other activities, such as undertak-
ing colour fundus photography and OCTs, with pre-
registration optometrists and other support staff.
The total average cost of an optometrist-led commu-
nity monitoring review was £52 per review (SD=£8). The
corresponding average cost for an ophthalmologist-led
HES monitoring review was £76 (SD=£44), as costed in
the IVAN trial.22 These ﬁgures do not include the down-
stream costs after the monitoring review, which were
part of the care pathway costs.
Cost-effectiveness of monitoring by optometrists compared
with ophthalmologists
Table 1 reports the care pathway cost, which depends on
how ophthalmologists’ and optometrists’ judgements
compare with the reference standard lesion classiﬁca-
tion. The pathway includes the cost of a monitoring con-
sultation itself and also downstream costs whenever
applicable (eg, ranibizumab injections and follow-up
visits based on the care cost pathway decision tree).
In terms of the 994 (795+142+57) vignettes rated as
reactivated in the reference standard lesion classiﬁca-
tion, the optometrists made more correct decisions than
the ophthalmologists (79.98% (795/994) compared with
74.04% (736/994)), and were less likely to misclassify
reactivated lesions as suspicious or quiescent.16 The
optometrists therefore showed greater sensitivity for
identifying reactivated lesions.
Conversely, the optometrists had lower speciﬁcity and
were three times more likely to incorrectly judge the 987
(105+234+648) truly quiescent vignettes as reactivated
(10.63% (105/987)) than their clinical counterparts
(3.55% (35/987), p<0.001 (χ2 test conducted in STATA)).
Table 2 reports the base case analysis of the cost-
effectiveness of optometrists as compared with ophthal-
mologists in performing monitoring reviews, taking the
average of the patient cost pathways described above.
The mean care pathway cost for each assessment is
similar between the two professional groups, equalling
£411 for optometrists and £397 for ophthalmologists,
and producing a cost difference of £13 (95% CI −£18 to
£45). The non-signiﬁcantly higher cost for optometrists
Table 1 Care pathway costs—base case analysis
Lesion status assessment Observations* (%)
Pathway cost†
Mean (SD)
Experts (true) Optometrists’ decision
Reactivated Reactivated 795 (39.43) £935.40 (45.50)
Reactivated Suspicious 142 (7.04) £103.61 (18.51)
Reactivated Quiescent 57 (2.83) £51.29 (9.08)
Suspicious Reactivated 10 (0.50) £118.12 (16.39)
Suspicious Suspicious 11 (0.55) £57.04 (9.10)
Suspicious Quiescent 14 (0.69) £52.96 (9.37)
Quiescent Reactivated 105 (5.21) £117.14 (32.61)
Quiescent Suspicious 234 (11.61) £78.31 (11.53)
Quiescent Quiescent 648 (32.14) £51.98 (8.23)
Experts (true) Ophthalmologists’ decision
Reactivated Reactivated 736 (36.51) £ 882.67 (46.41)
Reactivated Suspicious 196 (9.72) £153.18 (92.25)
Reactivated Quiescent 62 (3.08) £77.01 (45.49)
Suspicious Reactivated 1 (0.05) £877.38 (N/A)
Suspicious Suspicious 17 (0.84) £68.84 (31.00)
Suspicious Quiescent 17 (0.84) £60.57 (17.16)
Quiescent Reactivated 35 (1.73) £882.29 (38.00)
Quiescent Suspicious 146 (7.24) £150.34 (95.19)
Quiescent Quiescent 806 (39.98) £75.28 (44.72)
*The number of observations (ie, vignettes) is 4038, namely 2016 retreatment decisions by optometrists and 2016 retreatment decisions by
ophthalmologists.
†Pathway costs include the cost of a monitoring consultation and downstream costs (eg, injections and follow-up visits).
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is driven by the higher percentage of vignettes incor-
rectly classiﬁed as reactivated, thus incurring a larger
cost for the healthcare service from an unnecessary
ophthalmologist-led review. A slightly smaller percentage
of correct decisions was made by optometrists (84.4%)
compared with ophthalmologists (85.4%), a difference
that was neither statistically signiﬁcant (1.0%, 95% CI
−4.5% to 2.5%) nor clinically meaningful.16
With non-signiﬁcantly higher mean costs and
non-signiﬁcantly fewer correct treatment decisions,
community optometry review is dominated by ophthal-
mologist-led reviews, being more costly and less effective.
However, the differences are extremely small and not stat-
istically signiﬁcant: optometrist-led reviews increase the
total costs by only £13 per review (3% of the total cost of
the care pathway) and result in only one more incorrect
decision per 100 monitoring reviews conducted.
Furthermore, there remains uncertainty around this
ﬁnding. This is illustrated by the cost-effectiveness plane
in online supplementary ﬁgure A.1 (in the online
supplementary material) and the CEAC in ﬁgure 3,
which shows that the probability of optometrist-led
reviews being cost-effective compared with ophthalmolo-
gist-led monitoring reviews is between 7% and 30%
regardless of how much the NHS is willing to pay per
correct retreatment decision.
Sensitivity analyses 1–3 conﬁrm the results of the
primary (base case) analysis (see online supplementary
material), ﬁnding community optometry review domi-
nated by ophthalmologist-led reviews. In contrast, sensi-
tivity analysis 4 (which includes only the cost of the
initial monitoring consultation and excludes all down-
stream costs of treatment and subsequent monitoring,
see online supplementary material) indicates that if the
NHS is willing to pay no more than £600 per correct
retreatment decision, we can be 95% certain that
optometrists-led reviews are a cost-effective option to
ophthalmologist-led visits. It is important to emphasise,
however, that sensitivity analysis 4 excludes the costs
resulting from correct and incorrect decisions, which are
an integral part of the costs associated with a retreatment
decision. This highlights the importance of using even
simple decision models for capturing all the relevant
costs that pertain to a retreatment decision, so that ﬁnal
results are not biased. It also suggests that ﬁndings may
be sensitive to the assumptions underlying the decision
tree and, consequently, it becomes extremely important
to develop reasonable models of shared-care delivery
that are acceptable within current practice in community
optometrist scenarios and hospital eye settings.
Optometrist-led care was also found to be less costly
than monitoring by ophthalmologists in sensitivity ana-
lysis 5, in which patients referred by community optome-
trists were assumed to have a review of the pre-existing
images, rather than a full hospital monitoring consult-
ation. In this scenario, the care pathway for optometrist-
led monitoring was found to cost £9 (95% CI −£39 to
£22) less than ophthalmologist-led monitoring. Referring
patients to receive monitoring at community optometry
practices is therefore cost-effective in this scenario if the
NHS is willing to accept one additional incorrect retreat-
ment decision in order to save £870, and had a 69%
probability of being cost-effective if the NHS were willing
to pay £200 per correct retreatment decision.
DISCUSSION
This study suggests that community optometry-led
follow-up reviews for patients with quiescent nAMD
lesion is associated with non-signiﬁcantly higher costs
and marginally fewer correct treatment decisions
Table 2 Base case analysis of cost-effectiveness of a monitoring review performed by optometrists versus cost of a
monitoring review performed by ophthalmologists
Costs and effects
Optometrists
Mean (SD)
(observations, n=2016)
Ophthalmologists
Mean (SD)
(observations, n=2016)
Cost of a monitoring review (pathway cost) £410.78 (424.92) £397.33 (387.46)
Percentage of correct assessments 84.4% (36.3%) 85.4% (35.3%)
Incremental cost (95% CI) £13.45 (−£17.96 to £44.85)
Incremental benefit, percentage of correct assessments (95% CI) −1.0% (−4.5% to 2.5%)
Incremental cost per correct assessment* Optometrist-led care is dominated
*The 95% CI around the incremental cost-effectiveness ratio could not be defined.
Figure 3 Cost-effectiveness acceptability curve for
community optometry versus ophthalmologist-led care at a
hospital eye service—base case analysis.
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compared with ophthalmologist-led care, although the
difference in outcomes is not clinically meaningful16
and, when uncertainty around the joint distribution of
costs and effects is taken into account, it remains
unclear whether the differences between the two care
pathways are economically signiﬁcant.
The optometrists showed greater sensitivity for identi-
fying reactivated lesions compared with ophthalmolo-
gists. Given the hypothesised model of shared care, the
implication of this result is twofold. When an optom-
etrist correctly judges the lesion as reactivated, the con-
ﬁrmatory ophthalmologist-led monitoring review
assumed in the model will represent an unnecessary
cost. In contrast, when an ophthalmologist judges a
lesion to have reactivated, the model assumes that the
patient will receive ranibizumab without the need of a
second opinion: this avoids a further unnecessary moni-
toring review if the ophthalmologist’s judgement is
correct. When either optometrists or ophthalmologists
mistakenly judge reactivated lesions to be quiescent, this
will generate delays in treatment that may result in
deterioration in patient eyesight. This clinically import-
ant outcome, which occurred more commonly for
ophthalmologists, was not quantiﬁed in our analysis as it
lay beyond the 4-week time horizon.
Conversely, the optometrists had lower speciﬁcity and
were three times more likely to incorrectly judge truly
quiescent vignettes as reactivated than their clinical
counterparts. For optometrists, such mistakes result in
an unnecessary ophthalmologists-led monitoring review.
We assumed that this consultation would identify all
incorrect referrals, thereby avoiding unnecessary treat-
ment, although in practice some such referrals may be
missed. In contrast, if an ophthalmologist makes the
same error, the patient will undergo a costly treatment
which is unnecessary at that moment in time, simply
because there is no second check of the ophthalmolo-
gists’ diagnosis.
Results were sensitive to the assumptions underpin-
ning the proposed model of shared care. A ‘post hoc’
sensitivity analysis used a different care pathway, whereby
patients referred by optometrists had a review, by
ophthalmologists, of pre-existing OCT and colour
images to assess eligibility for treatment, as a form of
quality assurance, rather than a full hospital monitoring
consultation. This analysis found that optometrist-led
care could be cost-effective if the value that the NHS
places on each correct retreatment decisions is <£870.
Other care pathways could also be used, which are not
modelled here.
Based on the prevalence and incidence of nAMD,27–29
around 219 000 patients currently attend VEGF clinics in
England each month, of whom 52 000 (19%) have bilat-
eral disease. We assumed that patients would be referred
from the HES to community optometrists for monitor-
ing if they did not meet the IVAN retreatment criteria in
either eye 1 month after ﬁnishing a course of anti-VEGF
treatment. This suggests that ∼21 950 patients in
England may be eligible for referral to community
optometry each month, equating to 535 550 community
monitoring reviews per year, if patients are, on average,
quiescent for 2 months. The costing analysis suggests
that on average the initial monitoring consultation is
£24 cheaper if performed by community optometrists
rather than the HES, equating to initial savings of £12.7
million (£24×535 550) across NHS England. However,
this ﬁgure takes no account of the costs after the patient
is referred back to the HES for review and treatment.
Allowing for the costs accrued across the entire treat-
ment pathway using the base case analysis, community
optometry is on average £13 more costly and referring
patients for monitoring by community optometrists is
expected to cost an additional £7.2 million (95% CI −
£9.6 to £24.0 million) across England (£13 (95% CI −
£18 to £45)×535 550). In contrast, using the alternative
care pathway described in sensitivity analysis 5 (with
review of images rather than a repeat monitoring con-
sultation), community optometry could save £4.6 million
(£9×535 550). However, there is substantial uncertainty
around the incremental cost of shared care: within the
base case analysis, there is a 20% chance that
optometrist-led care could be cost-saving, compared with
a 71% chance in scenario 5.
These ﬁndings have to be interpreted in light of some
limitations of the study, resulting from the ‘virtual’
nature of the trial. First, costs were estimated using a
hypothetical model of shared care developed with the
input of clinicians and optometrists in the ECHoES trial
team. Despite attempts to conceive the model in a way
that could be as generalisable as possible, the shared
care model assumed here may not be considered an
adequate representation of all local circumstances/set-
tings and therefore speciﬁc adaptations may be appro-
priate. Sensitivity analyses suggested that results were
sensitive to some changes in the assumptions underpin-
ning the model.
Second, the shared model is based on evaluating only
one eye (a limitation of the trial; the IVAN trial did not
collect frequent images for the fellow eyes, so vignettes
based on information about both eyes could not be con-
structed). Considering bilateral disease would not change
the sensitivity and speciﬁcity of decisions for each eye,
but the rates of false-positive and false-negative referrals (at
the level of a patient) would almost certainly be affected.
More empirical data are needed on practitioners’ referral
decisions for patients with bilateral disease.
Third, there are limited data on whether the propor-
tions of reactivated (49%), inactive (49%) and suspi-
cious (2%) reference classiﬁcations among the vignettes
are representative; varying the proportions does not
change the sensitivity and speciﬁcity but does change
the positive and negative predictive values, that is, the
proportions of false positives and false negatives that are
observed16 and may affect cost-effectiveness.
Unfortunately, there is no direct information on these
proportions in the course of usual care, and this may
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depend on the ‘treatment-free interval’ that is chosen
before ‘discharging’ a patient with inactive disease to
optometric review. Data from the UK nAMD Database5
are most relevant; the median time to retreatment after
a 3-month treatment-free interval was 2.5 months
(equivalent to reactivation at 40%). The treatment fre-
quencies observed in the HARBOR and AURA studies3 4
suggested that treatment was needed on more than 50%
of the monthly visits.
Fourth, optometrists completing costing question-
naires had to answer questions on the resources that they
would need to implement a hypothetical shared care
scheme in their practice that is not currently routine,
which may have affected the accuracy of some responses,
especially with respect to volume of patients with nAMD
that the practice may accommodate. Finally, in order not
to overburden participants, the health economics ques-
tionnaire was not a compulsory section for participants,
which reduced the number of completed resource use
questionnaires. Mean imputation was also required due
to item non-response. However, those who did complete
the questionnaires varied substantially in terms of their
practice size and type, capturing heterogeneity of optom-
etry practice settings. The analysis also comprises a cost-
effectiveness analysis with a short time horizon and an
intermediate end point (correct retreatment decisions).
This end point does not distinguish between false posi-
tives (ie, unnecessary referrals) and false negatives (ie,
missed opportunities for timely treatment), which will
have very different impacts on costs and health and may
have different ceiling ratios. This could have affected the
results, particularly as optometrists tended to have more
false positives and fewer false negatives than ophthalmol-
ogists. Owing to the virtual trial setting, the analysis
could not take into consideration beneﬁts and costs
accrued to patients and their carers.
Part of the trial inclusion criteria for optometrists was
that they should not have had any prior exposure to
retina clinics or in-depth knowledge of macular morph-
ology. This was to ensure that we were evaluating a group
of optometrists that were similar to most community
optometrists. While we did provide some training in the
trial, this training was short. When considering the result
of non-inferiority, it is notable that the ophthalmologist
participants in the trial represented usual care in the
NHS. Both sets of participants were compared with the
reference standard who were retina specialists recognised
in their ﬁeld as experts in this condition. Therefore, we
can only speculate about what might happen to error
rates, and the difference in the types of error made, with
increasing experience in the groups studied. Without
feeding back expert classiﬁcations, we see no reason for
any difference in the error rates or types of error. With
feedback, one might expect the performance of both
groups to improve, but we think that the difference in
the rates of different types of error might be maintained,
given the different settings (primary vs secondary care)
in which decisions would be made.
A further point, which might support the introduction
of a model of shared care, is the consideration of
patient views for altering the balance of care. The travel
costs and time away from usual activities would most
likely be less with visits to a community optometrist and
this option might be preferred by patients. Although
patient’s preferences and costs were not directly
included in our analyses, qualitative work undertaken as
part of the ECHoES trial reported that there was enthu-
siasm among health professionals and service users
about the possibility of shared care for nAMD, as it was
felt to have the potential to relieve HES burden and rep-
resent a more patient-centred service.30
In summary, the base case analysis found that correct
retreatment decisions by optometrists were slightly less
common compared with ophthalmologists, leading to
marginally higher costs for the former—although not
statistically signiﬁcant. Sensitivity analyses that reﬂected
different practices across eye hospitals, indicated that
shared care pathways can be identiﬁed which may repre-
sent cost-effective models of shared care between com-
munity optometrists and ophthalmologists in the
management of nAMD, although in light of the uncer-
tainty around differences in outcome and cost it remains
unclear whether the differences between the two care
pathways are signiﬁcant in economic terms. The present
study has allowed the various potential ‘ingredients’ of a
future shared care model to be costed and represents an
important contribution to innovatively shape clinical
practice. ECHoES demonstrates that shared care will be
non-inferior to current care in the HES and with
repeated exposure to clinical situations and appropriate
feedback community optometrists’ skills can only
improve. Harnessing this body of skilled community-
based workforce has the potential to address the serious
shortages of specialist staff in the HES. This is particu-
larly timely because the UK NHS not only has the lowest
rate of ophthalmologists per capita within Europe8 but
also treats more patients with nAMD more intensively
than in other countries.31 This, on the one hand, allows
some of the best functional outcomes in Europe4 but,
on the other hand, makes an already burdensome work-
load even less manageable. Thus, expanding the clinical
role of non-medical staff, after appropriate training, is a
promising strategy to meet the challenge of shortage of
ophthalmologists in the HES. Further research could
assess the applicability of the proposed model of shared
care to other retinal diseases such as diabetic macular
oedema and retinal vein occlusion. In particular, data
are required on the downstream clinical pathways after
optometrist assessment and likely patient numbers who
could participate in such models.
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